Insider buying last 90 days
No open-market insider purchases were filed for MIRM in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Mirum Pharmaceuticals raised its 2026 net product sales guidance to $715 million-$720 million following third-quarter sales of $186 million, building on an earlier raise to $680-$700 million discussed alongside second-quarter results. The company also launched a sponsored genetic testing program with GeneDx for rare liver disease patients, part of its focus on treatments like Livmarli. Analyst activity was mixed in tone: Leerink Partners maintained its Outperform rating while lowering its price target to $140 from $154, and HC Wainwright & Co. maintained its Buy rating while raising its target to $202 from $200. CEO Christopher Peetz sold 20,000 shares at an average price of $90.00, for a total of $1,800,000.00.
MIRM closed at $93.18, down 0.6%, sitting between its 50-day average of $89.20 and 200-day average of $98.53. The GekkoIndex reads 49.5, placing the stock in the Neutral zone. The current price sits 18.5% below Gekko Fair Value of $114.36.
The next earnings date falls on 24 February 2027, 106 days out, beyond a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in their respective 90-day and 30-day windows. Seasonality over the next 20 trading days has averaged -4.5% across 5 years, rising in 2 of those years. Consensus among 12 covering firms stands at a Buy rating with a target of $153.43.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Mirum Pharmaceuticals scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
Averages disagree
Close $93.99 sits between the 50-day ($88.79) and 200-day ($98.41) averages, or the averages disagree.
See the chart52, Neutral
Reading 52 is in the Neutral zone.
See the GekkoIndex17.7% below
Price is 17.7% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 101 days
Next report Feb 24, 2027, 101 days away — outside a typical 20-trading-day hold.
See earnings−3.8% on average
From this point in the calendar, the next 20 trading days averaged −3.8% over 5 years, rising in 1 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Mirum Pharmaceuticals closed at $93.99 on Nov 13, 2026, +32.8% over the past year, inside a 52-week range of $63.23 to $130.00.
Use the left and right arrow keys to read daily values.
Put MIRM on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Mirum Pharmaceuticals works on medicines meant for patients facing uncommon and severely underserved illnesses, with much of its attention on disorders of the liver. The company is most recognized for LIVMARLI, a treatment taken by mouth that is being tested against progressive familial intrahepatic cholestasis, Alagille syndrome, and biliary atresia.
Alongside this, Mirum is also moving forward with Volixibat, aimed at treating intrahepatic cholestasis that occurs during pregnancy as well as primary sclerosing cholangitis. These two programs make up the main focus of what the company is building toward, as it works to turn early-stage research into approved treatments for people living with these conditions.
Mirum Pharmaceuticals traces its founding to 2018 and keeps its base in Foster City, California. Its stock trades on the NASDAQ exchange under the symbol MIRM.
Mirum Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 52, in the Neutral zone, up 3 points over five sessions.
Up 3 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 18 | −0.3% | +7.3% | ||
| Accumulation | 223 | +0.9% | +4.3% | ||
| Neutral (current zone) | 391 | +1.0% | +4.5% | ||
| Distribution | 62 | +2.4% | +1.7% | ||
| Selling | 8 | Too few readings yet | |||
Average MIRM share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Mirum Pharmaceuticals trades 17.7% below Gekko Fair Value of $114.27, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Mirum Pharmaceuticals shares are worth, recalculated every trading day.
$114.27
Gekko Fair Value, Nov 14, 2026
17.7% Undervalued
At the end of Aug 2026 the price was 23.6% below the estimate.
No open-market insider purchases were filed for Mirum Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for MIRM in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in MIRM were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
0of the funds Gekko tracks hold MIRM.
Mirum Pharmaceuticals reports on Feb 24, 2027 (101 days away), and beat the EPS estimate in 4 of its last 8 reports.
Feb 24, 2027
101 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | −$1.06 est −$0.74 | $176.2M est $166.3M | −9.8% |
| May 6, 2026 | −$13.43 est −$0.40 | $159.9M est $148.2M | −2.7% |
| Feb 25, 2026 | −$0.11 est $0.02 | $148.9M est $142.5M | −14.2% |
| Nov 4, 2025 | $0.05 est −$0.10 | $133.0M est $140.9M | −1.1% |
| Aug 6, 2025 | −$0.12 est −$0.31 | $127.8M est $130.1M | +15.4% |
| May 7, 2025 | −$0.30 est −$0.39 | $111.6M est $98.40M | +10.3% |
| Feb 26, 2025 | −$0.49 est −$0.25 | $99.41M est $96.64M | −5.9% |
| Nov 12, 2024 | −$0.30 est −$0.45 | $90.38M est $95.44M | +5.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Mirum Pharmaceuticals is $154.00, +63.8% from the last close, from 12 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 12 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 11 | H.C. Wainwright | $202 | +114.9% |
| Nov 11 | Citi | $194 | +106.4% |
| Nov 9 | J.P. Morgan | — | — |
| Nov 9 | Citi | $184 | +95.8% |
| Nov 5 | Morgan Stanley | $152 | +61.7% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Mirum Pharmaceuticals averaged −3.8% across the last 5 years, rising in 1 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.0% | 2 of 5 |
| Next 10 trading days | −0.6% | 2 of 5 |
| Next 15 trading days | −2.9% | 2 of 5 |
| Next 20 trading days | −3.8% | 1 of 5 |
| Next 30 trading days | −0.1% | 2 of 5 |
For scale, MIRM’s typical 20-trading-day move in either direction is about 8.7%.
Mirum Pharmaceuticals’s market cap is $6.14B and revenue of $670.8M over the last twelve months.
Coverage of Mirum Pharmaceuticals this week reads positive: 8 positive, 2 neutral and 1 negative headlines.
Mirum Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Mirum Pharmaceuticals’s market cap is $6.14B at the Nov 13, 2026 close of $93.99, with 65.28M shares outstanding.
The consensus analyst 12-month price target for Mirum Pharmaceuticals is $154.00, +63.8% from the last close. Of the 12 firms that rated the stock in the last 90 days, 12 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Mirum Pharmaceuticals is undervalued: the Nov 13, 2026 close of $93.99 is 17.7% below Gekko Fair Value of $114.27. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Mirum Pharmaceuticals is expected to report on Feb 24, 2027 (101 days away). Analysts expect earnings of −$0.62 per share on revenue of $194.5M. Mirum Pharmaceuticals beat the earnings estimate in 4 of its last 8 reports, moving 8.1% on average across the report.
Mirum Pharmaceuticals’s 52-week high is $130.00 and its 52-week low is $63.23; it closed at $93.99 on Nov 13, 2026, +32.8% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and earnings risk), 2 as mixed (trend and gekkoindex) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.